^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Javlor (vinflunine)

    i
    Other names: BMS-710485, F-12158, L0070 , BMS710485, BMS 710485, F12158, F 12158, L-0070, L 0070
    Associations

    News

    Trials
    Company:
    Pierre Fabre
    Drug class:
    Microtubule inhibitor
    Related drugs:
    Associations

    News

    Trials
    15d
    A clinical trial of sacituzumab tirumotecan to treat urothelial cancer (MK-2870-031) (2024-520014-22-00)
    P2/3, N=265, Recruiting, Merck Sharp & Dohme LLC
    New P2/3 trial
    |
    paclitaxel • docetaxel • Jiataile (sacituzumab tirumotecan) • Javlor (vinflunine)
    1m
    TroFuse-031: A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) (clinicaltrials.gov)
    P3, N=590, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    paclitaxel • docetaxel • Jiataile (sacituzumab tirumotecan) • Javlor (vinflunine)
    3ms
    TroFuse-031: A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) (clinicaltrials.gov)
    P3, N=590, Not yet recruiting, Merck Sharp & Dohme LLC
    New P3 trial
    |
    paclitaxel • docetaxel • Jiataile (sacituzumab tirumotecan) • Javlor (vinflunine)
    4ms
    A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) (clinicaltrials.gov)
    P3, N=608, Completed, Astellas Pharma Global Development, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    paclitaxel • docetaxel • Padcev (enfortumab vedotin-ejfv) • Javlor (vinflunine)
    9ms
    A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) (clinicaltrials.gov)
    P3, N=608, Active, not recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Aug 2025 --> Nov 2025
    Trial completion date
    |
    paclitaxel • docetaxel • Padcev (enfortumab vedotin-ejfv) • Javlor (vinflunine)
    9ms
    TROPiCS-04: Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread (clinicaltrials.gov)
    P3, N=712, Completed, Gilead Sciences | Active, not recruiting --> Completed
    Trial completion
    |
    paclitaxel • docetaxel • Trodelvy (sacituzumab govitecan-hziy) • Javlor (vinflunine)
    11ms
    Erdafitinib versus Chemotherapy in Fibroblast Growth Factor Receptor-Altered Advanced or Metastatic Urothelial Cancer After Progression on Anti-programmed Death-(Ligand) 1 Therapy: An Exploratory Analysis of the Asian Subpopulation in the THOR Phase 3 Study. (PubMed, Clin Genitourin Cancer)
    Erdafitinib showed improved survival compared with chemotherapy, with no new safety concerns in the Asian subpopulation. These findings were consistent with those for the overall study population in THOR Cohort 1 who received prior anti-PD-(L)1 therapy.
    P3 data • Journal
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    docetaxel • Balversa (erdafitinib) • Javlor (vinflunine)
    1year
    A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) (clinicaltrials.gov)
    P3, N=608, Active, not recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Apr 2025 --> Aug 2025
    Trial completion date
    |
    paclitaxel • docetaxel • Padcev (enfortumab vedotin-ejfv) • Javlor (vinflunine)
    over1year
    TROPiCS-04: Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread (clinicaltrials.gov)
    P3, N=696, Active, not recruiting, Gilead Sciences | Trial completion date: Jul 2025 --> Oct 2025 | Trial primary completion date: Jul 2025 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    paclitaxel • docetaxel • Trodelvy (sacituzumab govitecan-hziy) • Javlor (vinflunine)
    over1year
    A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) (clinicaltrials.gov)
    P3, N=608, Active, not recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Aug 2024 --> Feb 2025
    Trial completion date • Metastases
    |
    paclitaxel • docetaxel • Padcev (enfortumab vedotin-ejfv) • Javlor (vinflunine)
    over1year
    TROPiCS-04: Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread (clinicaltrials.gov)
    P3, N=696, Active, not recruiting, Gilead Sciences | Trial completion date: Oct 2024 --> Jul 2025 | Trial primary completion date: Oct 2024 --> Jul 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    paclitaxel • docetaxel • Trodelvy (sacituzumab govitecan-hziy) • Javlor (vinflunine)
    over1year
    Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma. (PubMed, J Health Econ Outcomes Res)
    An anchored MAIC was conducted according to the National Institute for Health and Care Excellence Decision Support Unit guidance, with physician's choice of chemotherapy (docetaxel/paclitaxel and vinflunine) as the common comparator. The MAIC indicates comparable efficacy of erdafitinib vs EV for overall survival and progression-free survival, with erdafitinib showing a higher probability of achieving deep responses. While erdafitinib is associated with slightly more adverse events compared with EV, these events seem to be less severe.
    Journal • Metastases
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    paclitaxel • docetaxel • Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv) • Javlor (vinflunine)